Answers are grounded in this paper and cite their sources.
Over the years, there has been significant interest in PEGylated lipid-based nanocarriers within the drug delivery field. The inevitable interplay between the nanocarriers and plasma protein plays a pivotal role in their
No takes yet. Share an insight, caveat, or question.
Pan et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: